(ACRV) Acrivon Therapeutics - Ratings and Ratios
Cancer, Drugs, Diagnostics, Platform, Pipeline
Description: ACRV Acrivon Therapeutics
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that leverages its proprietary generative phosphoproteomics platform to develop targeted oncology treatments. By utilizing its Acrivon Predictive Precision Proteomics (AP3) platform, the company creates companion diagnostics, known as OncoSignature, to identify patients likely to benefit from its therapies. This precision medicine approach enables Acrivon to tailor its treatments to specific patient populations, potentially increasing their efficacy.
The companys pipeline includes ACR-368, a CHK1 and CHK2 inhibitor being evaluated for the treatment of endometrial, platinum-resistant ovarian cancer, and certain squamous cell carcinomas. Additionally, Acrivon is developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor, and a preclinical cell cycle program. With a focus on precision oncology, Acrivon aims to address the needs of patients with tumors predicted to be sensitive to its medicines.
From a technical analysis perspective, ACRVs stock price has been trending downward, with its short-term and long-term moving averages (SMA20, SMA50, and SMA200) indicating a bearish sentiment. The Average True Range (ATR) suggests significant volatility, with a 16.48% daily price swing. Given the current price of $1.25, the stock is near its 52-week low of $1.10. However, a potential buying opportunity may arise if the stock price stabilizes above its SMA20 at $1.36.
Fundamentally, Acrivon Therapeutics has a relatively small market capitalization of $37.63M USD, and its lack of profitability is reflected in its negative P/E ratio and Return on Equity (RoE) of -46.18. As a clinical-stage biopharmaceutical company, significant investments in research and development are expected. The success of its lead candidates, particularly ACR-368, will be crucial in determining the companys future prospects.
Forecasting the future performance of ACRV requires a combination of technical and fundamental analysis. Based on the current technical trends and fundamental data, a potential price target for ACRV could be around $2.50, representing a 100% increase from its current price. This would be contingent upon the company announcing positive clinical trial results for ACR-368, securing additional funding, or achieving significant milestones in its pipeline development. However, the high volatility and bearish sentiment in the stocks technical indicators suggest that there are substantial risks associated with this investment.
ACRV Stock Overview
| Market Cap in USD | 41m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2022-11-15 |
ACRV Stock Ratings
| Growth Rating | -89.7% |
| Fundamental | 27.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -82.7% |
| Analyst Rating | 4.33 of 5 |
ACRV Dividends
Currently no dividends paidACRV Growth Ratios
| Growth Correlation 3m | 58.7% |
| Growth Correlation 12m | -88% |
| Growth Correlation 5y | -79.1% |
| CAGR 5y | -56.84% |
| CAGR/Max DD 3y | -0.60 |
| CAGR/Mean DD 3y | -0.82 |
| Sharpe Ratio 12m | -0.33 |
| Alpha | 0.12 |
| Beta | 0.872 |
| Volatility | 132.96% |
| Current Volume | 889.5k |
| Average Volume 20d | 226.9k |
| Stop Loss | 1.4 (-10.3%) |
| Signal | 0.46 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-86.0m TTM) > 0 and > 6% of Revenue (6% = 50.9k TTM) |
| FCFTA -0.43 (>2.0%) and ΔFCFTA -24.10pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.7k% (prev 9080 %; Δ 5658 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.45 (>3.0%) and CFO -70.8m > Net Income -86.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (38.5m) change vs 12m ago 6.45% (target <= -2.0% for YES) |
| Gross Margin -57.43% (prev 52.02%; Δ -109.4pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.44% (prev 0.82%; Δ -0.38pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -18.96
| (A) 0.79 = (Total Current Assets 138.4m - Total Current Liabilities 13.4m) / Total Assets 158.6m |
| (B) -1.50 = Retained Earnings (Balance) -237.7m / Total Assets 158.6m |
| warn (B) unusual magnitude: -1.50 — check mapping/units |
| (C) -0.48 = EBIT TTM -92.8m / Avg Total Assets 194.6m |
| (D) -15.28 = Book Value of Equity -237.5m / Total Liabilities 15.5m |
| Total Rating: -18.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.39
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -74.29% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda -0.05 = -2.50 |
| 6. ROIC - WACC (= -65.99)% = -12.50 |
| 7. RoE -50.78% = -2.50 |
| 8. Rev. Trend 11.43% = 0.86 |
| 9. EPS Trend 30.56% = 1.53 |
What is the price of ACRV shares?
Over the past week, the price has changed by -4.29%, over one month by +12.23%, over three months by +28.93% and over the past year by -79.47%.
Is Acrivon Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACRV is around 1.03 USD . This means that ACRV is currently overvalued and has a potential downside of -33.97%.
Is ACRV a buy, sell or hold?
- Strong Buy: 4
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACRV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.2 | 616% |
| Analysts Target Price | 11.2 | 616% |
| ValueRay Target Price | 1.2 | -24.4% |
Last update: 2025-09-06 04:30
ACRV Fundamental Data Overview
CCE Cash And Equivalents = 137.4m USD (Cash And Short Term Investments, last quarter)
P/B = 0.2947
Beta = 1.673
Revenue TTM = 848.0k USD
EBIT TTM = -92.8m USD
EBITDA TTM = -91.6m USD
Long Term Debt = 2.12m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 2.30m USD (from shortTermDebt, last quarter)
Debt = 4.41m USD (Calculated: Short Term 2.30m + Long Term 2.12m)
Net Debt = -38.6m USD (from netDebt column, last quarter)
Enterprise Value = -92.1m USD (40.9m + Debt 4.41m - CCE 137.4m)
Interest Coverage Ratio = unknown (Ebit TTM -92.8m / Interest Expense TTM 0.0)
FCF Yield = -74.29% (FCF TTM -68.4m / Enterprise Value -92.1m)
FCF Margin = -8070 % (FCF TTM -68.4m / Revenue TTM 848.0k)
Net Margin = -10.1k% (Net Income TTM -86.0m / Revenue TTM 848.0k)
Gross Margin = -57.43% ((Revenue TTM 848.0k - Cost of Revenue TTM 1.33m) / Revenue TTM)
Tobins Q-Ratio = 0.39 (Enterprise Value -92.1m / Book Value Of Equity -237.5m)
Interest Expense / Debt = 37.11% (Interest Expense 1.64m / Debt 4.41m)
Taxrate = 21.0% (US default)
NOPAT = -92.8m (EBIT -92.8m, no tax applied on loss)
Current Ratio = 10.31 (Total Current Assets 138.4m / Total Current Liabilities 13.4m)
Debt / Equity = 0.03 (Debt 4.41m / last Quarter total Stockholder Equity 143.0m)
Debt / EBITDA = -0.05 (Net Debt -38.6m / EBITDA -91.6m)
Debt / FCF = -0.06 (Debt 4.41m / FCF TTM -68.4m)
Total Stockholder Equity = 169.3m (last 4 quarters mean)
RoA = -54.20% (Net Income -86.0m, Total Assets 158.6m )
RoE = -50.78% (Net Income TTM -86.0m / Total Stockholder Equity 169.3m)
RoCE = -54.13% (Ebit -92.8m / (Equity 169.3m + L.T.Debt 2.12m))
RoIC = -54.81% (NOPAT -92.8m / Invested Capital 169.3m)
WACC = 11.19% (E(40.9m)/V(45.3m) * Re(9.23%)) + (D(4.41m)/V(45.3m) * Rd(37.11%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 6.72%
Discount Rate = 9.23% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -68.4m)
EPS Correlation: 30.56 | EPS CAGR: -3.67% | SUE: 2.95 | # QB: 3
Revenue Correlation: 11.43 | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for ACRV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle